3 Life Science Stocks to Sell Now

Advertisement

This week, the overall grades of three life science stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Enzo Biochem, Inc.’s (ENZ) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Enzo Biochem researches, develops, and manufactures health care products based on molecular biology and genetic engineering techniques. In Portfolio Grader’s specific subcategory of Equity, ENZ also gets an F. To get an in-depth look at ENZ, get Portfolio Grader’s complete analysis of ENZ stock.

This is a rough week for BG Medicin (BGMD). The company’s rating falls to D from the previous week’s C. BG Medicine develops and markets diagnostic tests. The stock gets F’s in Equity, Cash Flow and Sales Growth. For more information, get Portfolio Grader’s complete analysis of BGMD stock.

Luminex Corporation’s (LMNX) rating weakens this week, dropping to a D versus last week’s C. Luminex develops, manufactures and markets biological testing technologies with applications throughout the clinical diagnostic and life science industries. The stock also gets an F in Earnings Revisions. To get an in-depth look at LMNX, get Portfolio Grader’s complete analysis of LMNX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/04/3-life-science-stocks-to-sell-now-enz-bgmd-lmnx-9/.

©2024 InvestorPlace Media, LLC